Email this article to a friend

Printable Version

Articles Related to This Article: • The FDA Exposed: An Interview With Dr. David Graham, the Vioxx Whistleblower • Mercury Fillings Shattered! FDA, ADA Conspiracy to Poison Children with Toxic Mercury Fillings Exposed in Groundbreaking Lawsuit • FDA Running Extortion Racket: Natural Supplement Companies Threatened with Arrest if They Don't Pay Up Support NaturalNews advertisers - Advertise with NaturalNews Nutrition Can Save America! FREE report by Mike Adams, the Health Ranger, reveals why nutritional deficiencies are destroying America's health and economy... and how to restore America's future with real food.

(NaturalNews) The Food and Drug Administration is withholding guidelines on the production of generic versions of insulin and human growth hormone (HGH) that would save states millions of dollars, prompting the governors of Kansas, Minnesota, Vermont and Wisconsin to petition the agency to move more quickly.

In their petition, the governors wrote that documents outlining what the FDA expected of drug makers before generic versions of the two drugs could be approved had existed since at least 2002, and that "there are no scientific reasons for delaying the issuance of the guidance documents FDA already has drafted."

In March, the FDA refused to issue guidelines specific to generic versions of the two drugs, opting instead to develop guidelines pertaining to generic biotech drugs -- drugs based on proteins from living cells, also known as biopharmaceuticals or biologics.

The governors said in their letter that HGH and insulin are different from biologics, and should not be lumped in with other biotech drugs. They added that both have relatively simple structures and have a long history of safe usage.

FDA spokeswoman Susan Bro disagreed that the case was not that simple. "These products raise complicated scientific issues and we continue to work on them internally," she said. "FDA will review the governors' concerns carefully and respond accordingly."

While the FDA approved Novartis A.G.'s Omnitrope -- a generic version of the growth hormone Genotropin, made by Pfizer Inc. -- in May, they were careful to label the knockoff a "follow-on protein product" rather than an actual substitute for Genotropin, and added that it "does not establish a pathway" for future approvals of similar products.

"This delaying tactic is yet another way the FDA protects the financial interests of Big Pharma," explained Mike Adams, an outspoken critic of the FDA. "Generic drugs reduce the profits of the industry's most powerful drug companies, and each day the FDA delays the introduction of generics to the market, Big Pharma earns millions more in profits," he said. "The FDA is engaged in widespread antitrust activities designed to protect the prescription drug monopoly market in the United States."

###

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • The FDA Exposed: An Interview With Dr. David Graham, the Vioxx Whistleblower • Mercury Fillings Shattered! FDA, ADA Conspiracy to Poison Children with Toxic Mercury Fillings Exposed in Groundbreaking Lawsuit • FDA Running Extortion Racket: Natural Supplement Companies Threatened with Arrest if They Don't Pay Up	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/019880_the_FDA_drugs_growth_hormone.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/019880_the_FDA_drugs_growth_hormone.html">FDA delays generic drug guidelines that would save states millions</a>